Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 941-947 , October 2006

Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting

  • Douglas J. Veale, MD, FRCPI, FRCP(Lon)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +353 1 2773721; Fax: +353 1 2839240.

References 

  1. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis and Rheumatism. 1998;41(6):951–962
  2. van Tuyl M, Liu J, Wang J, et al. Role of oxygen and vascular development in epithelial branching morphogenesis of the developing mouse lung. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2005;288(1):L167–L178
  3. Reece RJ, Canete JD, Parsons WJ, et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1481–1485
  4. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. The Journal of Rheumatology. 2003;30:260–268
  5. Braverman IM, Yen A. Microcirculation in psoriatic skin. The Journal of Investigative Dermatology. 1974;62:493–502
  6. Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. The Journal of Investigative Dermatology. 1977;68:53–60
  7. Zaric DW. Capillary microscopy of the nailfold in psoriatic and rheumatoid arthritis. Scandinavian Journal of Rheumatology. 1981;10:249–252
  8. Augustin HG. Tubes, branches, and pillars: the many ways of forming a new vasculature. Circulation Research. 2001;89(8):645–647
  9. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(4):716–728[Epub 2006 Feb 9]
  10. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. The International Journal of Biochemistry & Cell Biology. 2006;38(3):333–357[Epub 2005 Nov 7]
  11. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994–1998
  12. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171–1180
  13. DeBusk LM, Chen Y, Nishishita T, et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis and Rheumatism. 2003;48(9):2461–2471
  14. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nature Medicine. 2006;12(2):235–239[Epub 2006 Feb 5]
  15. Markham T, Mullan R, Golden-Mason L et al. Resolution of endothelial activation and downregulation of the Tie2 receptor in psoriasis skin following infliximab therapy. Journal of the American Academy of Dermatology [in press].
  16. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(7):4349–4354[Epub 2002 Mar 26]
  17. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis and Rheumatism. 2004;50(10):3286–3295
  18. Tomoda R, Seto M, Hioki Y, et al. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clinical and Experimental Metastasis. 2005;22(7):559–564[Epub 2006 Feb 11]
  19. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. The New England Journal of Medicine. 1995;333(3):137–141
  20. Wilasrusmee C, Yusupov I, Ondocin P, et al. Angiocidal effect of cyclosporin A: a new therapeutic approach for pathogenic angiogenesis. International Angiology: A Journal of the International Union of Angiology. 2005;24(4):372–379
  21. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis and Rheumatism. 1998;41:1258–1265
  22. Takahashi H, Kato K, Miyake K, et al. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clinical and Experimental Rheumatology. 2005;23(4):455–461
  23. Sumariwalla PF, Cao Y, Wu HL, et al. The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis. Arthritis Research and Therapy. 2003;5:R32–R39
  24. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–285
  25. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(2):223–231
  26. Park YW, Kang YM, Butterfield J, et al. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. American Journal of Pathology. 2004;165(6):2087–2098
  27. Lee SD, Chen LM, Kuo WW, et al. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clinica Chimica Acta. 2006;367(1–2):62–68[Epub 2006 Jan 9]
  28. Kim HJ, Kim TY. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. British Journal of Dermatology. 2005;152:418–425
  29. Kuo GH, Prouty C, Wang A, et al. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. Journal of Medicinal Chemistry. 2005;24:1886–1900
  30. Voskas D, Jones N, Van Slyke P, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. American Journal of Pathology. 2005;166:843–855
  31. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology. 2005;44:126–129

PII: S1521-6942(06)00052-0

doi: 10.1016/j.berh.2006.05.004

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 941-947 , October 2006

Article Tools